B2i Digital Named Marketing Partner for 15th Annual ROTH London Conference
B2i Digital Will Showcase Participating Companies to Its Investor Community of Over 1.3 Million
NEW YORK, NY - May 18, 2025 (NEWMEDIAWIRE) - B2i Digital, Inc. will once again serve as the marketing partner for the 15th Annual ROTH London Conference, an exclusive, invite-only event connecting executive management from approximately 70 companies with institutional investors. The conference will be held June 2426, 2025, at the Four Seasons Hotel London at Park Lane.
ROTH's London Conference offers 1-on-1 and small group meetings between company leaders and investors across a range of sectors. These 40-minute sessions are designed to provide deeper insight into each company's business model, growth strategy, and long-term vision. The event also includes networking opportunities throughout the three-day schedule.
As the Marketing Partner, B2i Digital will publish profiles of the presenting companies on its platform, https://b2idigital.com/roth-15th-annual-london-conference and across 11 social media platforms. These profiles help participating companies reach retail, institutional and family office investors globally.
"B2i Digital is proud to support the ROTH London Conference again this year," said David Shapiro, CEO of B2i Digital. "We know that if a conference has the ROTH name on it, it will be a successful event with top-tier companies and fully vetted investors. This will be our final major event until fall, and we strongly encourage all investors who are able to attend."
Participation in the ROTH London Conference is by invitation only and subject to approval by ROTH. Investors interested in attending should contact their ROTH representative or request registration via the official site.
About B2i Digital, Inc.
B2i Digital, Inc. partners with a select group of public companies, investor conferences and essential capital markets advisors through its Featured Company, Featured Conference and Featured Expert programs. It leverages the latest digital marketing technologies, its network of 1.3 million investors and targeted introductions to bring together key players in the markets. B2i Digital was founded in 2021 by David Shapiro, previously an investment banker and Chief Marketing Officer at Maxim Group LLC and its investor awareness platform, M-Vest.com.
B2i Digital Contact Information:
David ShapiroChief Executive OfficerB2i Digital, Inc.https://b2idigital.com/212.579.4844 Officedavid@b2idigital.com
https://www.linkedin.com/in/davidshapironychttps://www.linkedin.com/company/b2i-digitalhttps://x.com/b2idigitalhttps://www.facebook.com/b2idigitalhttps://www.instagram.com/b2i_digitalhttps://www.youtube.com/@b2idigitalhttps://stocktwits.com/B2iDigitalhttps://www.reddit.com/user/b2idigital/https://www.pinterest.com/b2idigital/https://www.tiktok.com/@b2idigitalhttps://www.threads.net/@b2i_digitalhttps://bsky.app/profile/b2idigital.bsky.social
About ROTH Capital Partners, LLC
ROTH MKM is a relationship-driven investment bank focused on serving growth companies and their investors. Our full-service platform provides capital raising, high-impact equity research, macroeconomics, sales and trading, technical insights, derivatives strategies, M&A advisory, and corporate access. Headquartered in Newport Beach, California, ROTH MKM is a privately held, employee-owned organization and maintains offices throughout the U.S. For more information on ROTH MKM, please visit www.roth.com.
Investor Contact: ROTH MKMIsabel Mattson-PainManaging Director, Chief Marketing Officerimattson-pain@roth.comhttps://www.linkedin.com/company/rothcapitalpartners/https://www.roth.com
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
6 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline. One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates. A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals. The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM). According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases. While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
